Graphite Bio to Pay Special Dividend Linked to Lenz Therapeutics Merger

Dow Jones03-09

By Ben Glickman

 

Graphite Bio will pay a special dividend connected to its merger with Lenz Therapeutics.

The South San Francisco, Calif.-based gene editing company said Friday it estimated the special dividend will be $1.03 a share.

The total value of the special dividend won't exceed $60 million, subject to certain adjustments in the merger agreement, according to Graphite Bio. The exact amount of the dividend will be determined after deducting certain cash amounts as outlined in the merger agreement.

The payment of the dividend is conditioned on the merger closing. Graphite Bio shareholders will vote on the deal at a March 14 meeting, with closing expected March 21.

Graphite Bio and Lenz said in November they planned to merge in an all-stock deal.

 

Write to Ben Glickman at ben.glickman@wsj.com

 

(END) Dow Jones Newswires

March 08, 2024 17:16 ET (22:16 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment